Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 441Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Hematologic Neoplasms 220Leukemia, Lymphocytic, Chronic, B-Cell 186Myelodysplastic Syndromes 162Leukemia 131Lymphoma 92Lymphoma, Non-Hodgkin 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Multiple Myeloma 69Recurrence 59Leukemia, Myelomonocytic, Chronic 58Neoplasms 54Leukemia, Biphenotypic, Acute 48Burkitt Lymphoma 48Myeloproliferative Disorders 46Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, Large B-Cell, Diffuse 43Lymphoma, Mantle-Cell 41Hodgkin Disease 39Lymphoma, Follicular 34Lymphoma, B-Cell 33Lymphoma, B-Cell, Marginal Zone 27Leukemia, B-Cell 27Waldenstrom Macroglobulinemia 26Anemia, Refractory, with Excess of Blasts 25Primary Myelofibrosis 24Myelodysplastic-Myeloproliferative Diseases 21Leukemia, Myeloid, Chronic-Phase 19Hematologic Diseases 19

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tumor Lysis Syndrome × Other hematologic neoplasm × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡